Nano-Encapsulated Aprepitant Enhances Anticancer Potency in Lung Cancer Cells.
INTRODUCTION/OBJECTIVE The repurposing of aprepitant (APR), a clinically approved NK-1R antagonist, represents a promising anticancer strategy; however, its rapid systemic clearance limits its therapeutic efficacy. This study aimed to design and systematically evaluate PLGA- and ERS-based APR nanoparticles, characteriz...